NCT01101594 - A Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2010

Primary Completion Date

July 31, 2013

Study Completion Date

July 31, 2013

Conditions

Multiple Myeloma

Interventions

DRUG

hLL1-DOX (the doxorubicin conjugate of milatuzumab)

hLL1-DOX will be administered intravenously (through a vein) on days 1, 4, 8 \& 11 every 21 days for up to 8 treatment cycles. 4 different dose levels of hLL1-DOX will be studied for safety and tolerability.

Trial Locations (5)

19104

University Hospital of Pennsylvania, Philadelphia

30068

Georgia Cancer Specialists, Atlanta

32806

MD Anderson Orlando, Orlando

77030

MD Anderson Center, Houston

07601

Hackensack University Medical Center, Hackensack